MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ultragenyx Pharmaceutical
RARE
|
+$35.2M |
| 2 |
Cullinan Therapeutics
CGEM
|
+$30.9M |
| 3 |
BioAge Labs
BIOA
|
+$30.1M |
| 4 |
Taysha Gene Therapies
TSHA
|
+$26.6M |
| 5 |
Abivax
ABVX
|
+$25.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agios Pharmaceuticals
AGIO
|
+$44.2M |
| 2 |
Xenon Pharmaceuticals
XENE
|
+$34.2M |
| 3 |
Evommune
EVMN
|
+$33.5M |
| 4 |
Cytokinetics
CYTK
|
+$33M |
| 5 |
DBV Technologies
DBVT
|
+$29.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
MPM BioImpact's Q2 2026 Portfolio in Review
As of Q2 2026, MPM BioImpact held 48 positions worth $1.64B, up 27% from $1.29B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
MPM BioImpact withdrew a net $93M in Q2 2026, closing 11 positions and reducing 22 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $44.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, MPM BioImpact opened a new position in Ultragenyx Pharmaceutical worth $47.4M.
- MPM BioImpact's largest Q2 2026 buy was Ultragenyx Pharmaceutical: 1,418,215 shares worth $47.4M.
- MPM BioImpact added most to Cullinan Therapeutics in Q2 2026, an estimated $30.9M increase.
- MPM BioImpact's biggest Q2 2026 reduction was DBV Technologies, cutting an estimated $29.2M.
- MPM BioImpact fully exited Agios Pharmaceuticals in Q2 2026, selling an estimated $44.2M.
- MPM BioImpact's ten largest holdings make up 55% of its $1.64B portfolio in Q2 2026.
- MPM BioImpact opened 7 new positions and closed 11 in Q2 2026.
- MPM BioImpact's portfolio value rose 27% quarter-over-quarter to $1.64B.
Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.